ADVM News and Press, Adverum Biotechnologies Inc.

2024-07-17 15:35:06 ET Adverum Biotechnologies, Inc. (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Call July 17, 2024 08:00 AM ET Company Participants Mike Zanoni - Head of IR Laurent Fischer - President & CEO Charles Wykoff - Director of R...

A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...

2024-07-17 09:26:23 ET More on Adverum Biotechnologies Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy Seeking Alpha’s Quant Rating on Adverum Biotechnologies Historical earnings data for Adverum Biotechnologies Financial i...

-   6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks -   Efficacy: 76% of 6E10 patients were injection free, with maintained visual acuity and fluid contr...

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the inte...

REDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executi...

REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointments of Dr. Rabia Gurses Ozden to the Compa...

2024-05-26 12:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-09 17:34:55 ET More on Adverum Biotechnologies Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy Seeking Alpha’s Quant Rating on Adverum Biotechnologies Historical earnings data for Adverum Biotechnologies Financial i...

- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17 th , 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 20...